Prolylcarboxypeptidase independently activates plasma prekallikrein (Fletcher factor)

Current Molecular Medicine

Volumn 14, Issue 9, 2014, Pages 1173-1185

  Wang, J ^a   Matafonov, A ^b   Madkhali, H ^a   Mahdi, F ^a   Watson, D ^c   Schmaier, A H ^d   Gailani, D ^b   Shariat Madar, Z ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Diabetes; Hormones; Inflammation; Kallikrein; Obesity; Renin angiotensin system

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN III; PREKALLIKREIN; PROLINE CARBOXYPEPTIDASE; CARBOXYPEPTIDASE; LYSOSOMAL PRO-X CARBOXYPEPTIDASE;

AMINO ACID SEQUENCE; ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; MOLECULAR DOCKING; PEPTIDE MAPPING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; SITE DIRECTED MUTAGENESIS; CELL LINE; CHEMISTRY; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME SPECIFICITY; KINETICS; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; CARBOXYPEPTIDASES; CATALYTIC DOMAIN; CELL LINE; ENZYME ACTIVATION; ENZYME ASSAYS; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; PREKALLIKREIN; PROTEOLYSIS; SUBSTRATE SPECIFICITY;

EID: 84926307592     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666141015153519     Document Type: Article

References (42)

1. Mallela J, Perkins R, Yang J, Pedigo S, Rimoldi JM, Shariat-Madar Z. The functional importance of the N-terminal region of human prolylcarboxypeptidase. Biochem Biophys Res Commun 2008; 374: 635-640.
2. Wallingford N, Perroud B, Gao Q, et al. Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest 2009; 119: 2291-2303.
3. Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdos EG. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 1978; 253: 5927-5931.
4. Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Rojkjaer R, Schmaier AH. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol 2001; 280: H1821-H1829.
5. Wiggins RC. Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein. J Biol Chem 1983; 258: 8963-8970.
6. Colman RW, Mattler L, Sherry S. Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest 1969; 48: 11-22.
7. Scott CF, Silver LD, Purdon AD, Colman RW. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem 1985; 260: 10856-10863.
8. Lewis GP, Work T. Formation of bradykinin or bradykinin-like substances by the action of plasmin on plasma proteins. J Physiol 1957; 135: 7-8P.
9. Moreira CR, Schmaier AH, Mahdi F, da MG, Nader HB, Shariat-Madar Z. Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett 2002; 523: 167-170.
10. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002; 277: 17962-17969.
11. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006; 95: 1003-1010.
12. Zhu L, Carretero OA, Liao TD, et al. Role of prolylcarboxypeptidase in angiotensin II type 2 receptormediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 2010; 56: 384-390.
13. Zhu L, Carretero OA, Xu J, et al. Angiotensin II type 2 receptor-stimulated activation of plasma prekallikrein and bradykinin release: role of SHP-1. Am J Physiol Heart Circ Physiol 2012; 302: H2553-H2559.
14. Hooley E, McEwan PA, Emsley J. Molecular modeling of the prekallikrein structure provides insights into high-molecularweight kininogen binding and zymogen activation. J Thromb Haemost 2007; 5: 2461-2466.
15. Chajkowski SM, Mallela J, Watson DE, et al. Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase. Biochem Biophys Res Commun 2011; 405: 338-343.
16. Mallela J, Perkins R, Yang J, Pedigo S, Rimoldi JM, Shariat-Madar Z. The functional importance of the N-terminal region of human prolylcarboxypeptidase. Biochem Biophys Res Commun 2008; 374: 635-640.
17. Soisson SM, Patel SB, Abeywickrema PD, et al. Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase. BMC Struct Biol 2010; 10: 16.
18. Richardson JS, Richardson DC. Amino acid preferences for specific locations at the ends of alpha helices. Science 1988; 240: 1648-1652.
19. Friberger P, Gallimore MJ. Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma. Adv Exp Med Biol 1986; 198 Pt B: 543-548.
20. Chung DW, Fujikawa K, McMullen BA, Davie EW. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986; 25: 2410-2417.
21. Shariat-Madar Z, Rahimy E, Mahdi F, Schmaier AH. Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells. Am J Physiol Heart Circ Physiol 2005; 289: H2697-H2703.
22. Motta G, Rojkjaer R, Hasan AA, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 1998; 91: 516-528.
23. Colman RW, Wachtfogel YT, Kucich U, et al. Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood 1985; 65: 311-318.
24. Fuchs S, Kasher R, Balass M, et al. The binding site of acetylcholine receptor: from synthetic peptides to solution and crystal structure. Ann N Y Acad Sci 2003; 998: 93-100.
25. Chen S, Gfeller D, Buth SA, Michielin O, Leiman PG, Heinis C. Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids. Chembiochem 2013; 14: 1316-1322.
26. Fletcher JT, Finlay JA, Callow ME, Callow JA, Ghadiri MR. A combinatorial approach to the discovery of biocidal sixresidue cyclic D,L-alpha-peptides against the bacteria methicillin-resistant Staphylococcus aureus (MRSA) and E. coli and the biofouling algae Ulva linza and Navicula perminuta. Chemistry 2007; 13: 4008-4013.
27. Bierzynski A. Methods of peptide conformation studies. Acta Biochim Pol 2001; 48: 1091-1099.
28. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 2004; 103: 4554-4561.
29. Bernardo MM, Day DE, Olson ST, Shore JD. Surfaceindependent acceleration of factor XII activation by zinc ions. I. Kinetic characterization of the metal ion rate enhancement. J Biol Chem 1993; 268: 12468-12476.
30. Friedrich R, Panizzi P, Fuentes-Prior P, et al. Staphylocoagulase is a prototype for the mechanism of cofactorinduced zymogen activation. Nature 2003; 425: 535-539.
31. Adams GN, LaRusch GA, Stavrou E, et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 2011; 117: 3929-3937.
32. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-3843.
33. Abildgaard CF, Harrison J. Fletcher factor deficiency: family study and detection. Blood 1974; 43: 641-644.
34. Liu J, Gao BB, Clermont AC, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med 2011; 17: 206-210.
35. Bird JE, Smith PL, Wang X, et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost 2012; 107: 1141-1150.
36. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311.
37. Adams GN, Stavrou EX, Fang C, et al. Prolylcarboxypeptidase promotes angiogenesis and vascular repair. Blood 2013; 122: 1522-1531.
38. Jeong JK, Szabo G, Raso GM, Meli R, Diano S. Deletion of prolyl carboxypeptidase attenuates the metabolic effects of diet-induced obesity. Am J Physiol Endocrinol Metab 2012; 302: E1502-E1510.
39. Grobe N, Weir NM, Leiva O, et al. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Physiol Cell Physiol 2013; 304: C945-C953.
40. Than A, Leow MK, Chen P. Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways. J Biol Chem 2013; 288: 15520-15531.
41. Fraga-Silva RA, Pinheiro SV, Goncalves AC, Alenina N, Bader M, Santos RA. The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med 2008; 14: 28-35.
42. Fang C, Stavrou E, Schmaier AA, et al. Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/-mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood 2013; 121: 3023-3032.